Edward Lee Carter: Why Clinically Relevant Nonmajor Bleeding Demands Anticoagulation Stewardship?
Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn about a recent article by Deborah M. Siegal et al., published in Circulation, adding:
“‘Nonmajor’ bleeding does not mean inconsequential bleeding.
A new COMBINE-AF analysis in Circulation pooled patient-level data from 73,737 anticoagulated patients across five pivotal atrial fibrillation trials.
Over approximately two years, the estimated cumulative incidence of clinically relevant extracranial bleeding was 26%:
- 7% major bleeding
- 19% clinically relevant nonmajor bleeding
The second category matters.
These events may require medical evaluation, treatment, or interruption of anticoagulation-and can affect quality of life, adherence, and whether a patient remains protected from stroke.
The strongest predictors included hemoglobin below 12 g/dL and creatinine clearance below 60 mL/min.
Concomitant antiplatelet therapy and NSAID use were among the other important signals.
Perhaps the most revealing finding was what the analysis could not explain: measured baseline factors accounted for only about two-thirds of the population-level bleeding risk.
That does not mean two-thirds of bleeding is preventable. It suggests that our usual baseline variables do not capture the entire picture.
Dynamic factors-frailty, changing renal function, medication exposure, vascular fragility, or occult disease-may account for part of the remaining risk.
The lesson is not to avoid anticoagulation. For many patients with AF, it remains one of our most effective tools for preventing disabling stroke
The lesson is that anticoagulation stewardship cannot end when the prescription is written.
A clinically relevant bleed should trigger a structured review:
- Is the agent and labeled dose still appropriate?
- Have renal function or hemoglobin changed?
- Does aspirin-or any concomitant antiplatelet-still have a current indication?
- Is the patient using a prescribed or OTC NSAID?
- Does the bleeding site require evaluation for an underlying lesion or disease?
- Can we treat the cause while preserving stroke protection?
The response should not be automatic: neither dismiss the bleed nor reflexively stop or underdose anticoagulation without reassessing the patient
Patients often live in the large middle ground between “no bleeding” and “major hemorrhage.”
How we manage that middle ground may determine whether they can safely remain protected from stroke.
Siegal DM, et al. Circulation. Published online August 4, 2026.”
Title: Incidence and Predictors of Extracranial Bleeding on Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A COMBINE-AF Analysis
Authors: Deborah M. Siegal, Marc Carrier, M. Cecilia Bahit, Jackie Bosch, Alexander P. Benz, Brian Bergmark, Robert P. Giugliano, Christopher B. Granger, Victorien Monguillon, Martin O’Donnell, Jonas Oldgren, Manesh R. Patel, Rohin K. Reddy, Lars Wallentin, Qilong Yi, Andre Zimerman, John Eikelboom
Other posts featuring Edward Lee Carter on Hemostasis Today.
-
Aug 13, 2026, 10:31Brad Wilson: Clinical Insights from the Landmark ESC 2026 Trials
-
Aug 13, 2026, 10:23Rania Baleela: Evaluating Bedside Diagnostics and VICC Outcomes in Hemotoxic Snakebite
-
Aug 13, 2026, 10:11Christina Kounoudi: Low-Dose vs. Therapeutic Anticoagulation in Extended VTE Prophylaxis
-
Aug 13, 2026, 10:10Jean Connors: Can Prothrombin Levels Improve Antiphospholipid Syndrome Risk Assessment?
-
Aug 13, 2026, 09:40Neel Bhut: Can AI Help Us Make Gene Therapy More Efficient?
-
Aug 13, 2026, 08:23Sally Mandour: The Diagnostic Challenge of Hypocellular Bone Marrow Failure
-
Aug 13, 2026, 08:11Cristiana Coneru: How the Gut Microbiome Influences Venous Thrombosis
-
Aug 13, 2026, 06:36Steffen Uffenorde: Improving Access to Automated Red Cell Exchange in SCD
-
Aug 12, 2026, 23:16A Rare Case of Glanzmann Thrombasthenia and VWD in the Same Patient – Glanzmann’s Research Foundation